Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-27T22:14:19.243Z Has data issue: false hasContentIssue false
  • English
  • Français

Nuclear Magnetic Resonance Study of Cerebrospinal Fluid From Patients With Multiple Sclerosis

Published online by Cambridge University Press:  18 September 2015

Lynch Joanna ,
Peeling James ,
Auty Anthony  and
R. Sutherland Garnette
Lynch Joanna*
Affiliation:
Departments of Surgery (Neurosurgery) (J.L., G.R.S.); Pharmacology and Therapeutics (J.P., G.R.S.); Radiology (J.P.); and Medicine (Neurology) (A.A.);The University of Manitoba, Winnipeg
Peeling James*
Affiliation:
Departments of Surgery (Neurosurgery) (J.L., G.R.S.); Pharmacology and Therapeutics (J.P., G.R.S.); Radiology (J.P.); and Medicine (Neurology) (A.A.);The University of Manitoba, Winnipeg
Auty Anthony*
Affiliation:
Departments of Surgery (Neurosurgery) (J.L., G.R.S.); Pharmacology and Therapeutics (J.P., G.R.S.); Radiology (J.P.); and Medicine (Neurology) (A.A.);The University of Manitoba, Winnipeg
R. Sutherland Garnette*
Affiliation:
Departments of Surgery (Neurosurgery) (J.L., G.R.S.); Pharmacology and Therapeutics (J.P., G.R.S.); Radiology (J.P.); and Medicine (Neurology) (A.A.);The University of Manitoba, Winnipeg
*
Foothills Hospital, Division of Neurosurgery, 1403 - 29 Street N.W., Calgary, Alberta Canada T2N 2Y9
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Proton nuclear magnetic resonance (NMR) spectroscopy was used to examine cerebrospinal fluid (CSF) from patients (n = 30) with actively progressive multiple sclerosis (MS). Metabolite concentrations obtained from the spectra were compared to those determined from the spectra of CSF from control patients (n = 27) with benign spinal disorders. No significant difference was found between the 2 groups for most constituents, including lactate, glutamine, citrate, creatine and creatinine, and glucose. Acetate levels were significantly higher in MS patients, while formate levels were significantly lower, than the controls. There were no significant differences in metabolite concentrations in CSF from early and longstanding MS patients. A peak due to an unidentified compound was found at 2.82 ppm in the spectra of CSF from patients with actively progressive MS, but not in the spectra of CSF from the controls. The peak was not found in spectra of CSF from patients with AIDS dementia complex (n = 9) or Parkinson's disease (n = 5), but it did appear in spectra of CSF from 1 patient with Jakob-Creutzfeldt disease (out of 3 examined) and from 1 patient (out of 7) with Guillan-Barré disease. The unidentified compound is volatile and, from the chemical shift of the observed NMR peak, is probably an N-methyl compound. As such, it may be an intermediate in the cholino-glycine cycle, in which an abnormality has been proposed to exist in MS patients.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 20 , Issue 3 , August 1993 , pp. 194 - 198
Copyright
Copyright © Canadian Neurological Sciences Federation 1993

References

REFERENCES

1.Cuzner, ML. Recent biochemical and immunological observations in multiple sclerosis. Neuropathol App Neurobiol 1980; 6: 405–414.CrossRefGoogle ScholarPubMed
2.Adams, CW, Poston, RN, Buk, SJ. Pathology, histochemistry and immunocytoehemistry of lesions in acute multiple sclerosis. J Neurol Sci 1989; 92: 291–306.CrossRefGoogle ScholarPubMed
3.Adams, CW. The onset and progression of the lesion in multiple sclerosis. J Neurol Sci 1975; 25: 165–182.CrossRefGoogle ScholarPubMed
4.Gerstl, B, Eng, LF, Travaststjerna, MG, Smith, KL, Kruse, SL. Lipids and proteins in multiple sclerosis white matter. J Neurochem 1970; 17: 677–689.CrossRefGoogle ScholarPubMed
5.Hirsch, HE, Parks, ME. The quantitative histochemistry of multiple sclerosis: some biochemical parameters of plaque activity and progression. J Neurochem 1979; 32: 505–513.CrossRefGoogle Scholar
6.Zavalishin, IA, Dziuba, AN, Khokhlov, AP, Savchenko, Iu N. Znachenie N-metilaminokislot v diagnostike i pataogeneze ras-seiannogo skleroza. Vrach Delo 1987; 12: 68–70.Google Scholar
7.Peeling, J, Sutherland, GR. High-resolution 1H NMR spectroscopy studies of extract of human cerebral neoplasms. Mag Reson Med 1992; 24: 123–136.CrossRefGoogle ScholarPubMed
8.Peeling, J, Wong, D, Sutherland, GR. Nuclear magnetic resonance study of regional metabolite levels after forebrain ischemia in fats. Stroke 1989; 20: 633–641.CrossRefGoogle Scholar
9.Bell, JD, Brown, JCC, Sadler, PJ, et al.High resolution proton nuclear magnetic resonance studies of human cerebrospinal fluid. Clin Sci 1987; 72: 563–570.CrossRefGoogle ScholarPubMed
10.Petroff, OAC, Yu, RK, Ogino, T. High resolution proton magnetic resonance analysis of human cerebrospinal fluid. J Neurochem 1986; 47: 1270–1276.CrossRefGoogle ScholarPubMed
11.Paty, DW, Oger, JJF, Kastrukoff, LF, et al.MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked, oligoclonal banding and CT. Neurology 1988; 38: 180–185.CrossRefGoogle Scholar
12.Honig, LS, Siddharthan, R, Sheremata, WA, Sheldon, JJ, Sazant, A. Multiple sclerosis: correlation of magnetic resonance imaging with cerebrospinal fluid findings. J Neurosurg Neurol Psychiatry 1988; 51: 277–280.CrossRefGoogle ScholarPubMed
13.Poser, CM, Paty, DW, Scheinberg, L, et al.New diagnostic criteria for multiple sclerosis. In: Poser, CM, ed. The Diagnosis of Multiple Sclerosis. New York: Thieme-Stratton 1984: 225–229.Google Scholar
14.McGale, EH, Pye, IF, Stonier, C, Hutchison, EC, Aber, GM. Studies of the inter-relationship between cerebrospinal fluid and plasma amino acid concentrations in normal individuals. J Neurochem 1977; 29: 291–297.CrossRefGoogle ScholarPubMed
15.Diem, K, Lentner, C. Scientific Tables, 7th Edition, Ciba-Geigy, Basle 1970: 635–640.Google Scholar
16.Youmans, JR. Cerebrospinal fluid. In: Neurological Surgery, vol. I, 2nd Edition, Toronto: W.B. Saunders Co. 1982: 423–486.Google Scholar
17.Nagai, Y, Kanfer, JN, Tourtellotte, WW. Preliminary observations of gangliosides of normal and multiple sclerosis cerebrospinal fluid. Neurology 1973; 23: 945–948.CrossRefGoogle ScholarPubMed
18.Thomson, AJ, Brazil, J, Feighery, C, et al.CSF myelin basic protein in multiple sclerosis. Acta Neurol Scand 1985; 72: 577–583.CrossRefGoogle ScholarPubMed
19.Neu, I, Woelk, H. Investigations of the lipid metabolism of the white matter in multiple sclerosis: changes in glycero-phosphatides and lipid-splitting enzymes. Neurochem Res 1982; 7: 727–735.CrossRefGoogle ScholarPubMed
20.Qureshi, GA, Baig, MS. Quantitation of free amino acids in biological samples by high performance liquid chromatography. Application of the method in evaluating amino acid levels in cerebrospinal fluid and plasma of patients with multiple sclerosis. J Chromatogr 1988; 459: 237–244.Google ScholarPubMed
21.Arnold, DL, Matthews, PM, Francis, GS, O'Connor, J, Antel, JP. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurology 1992; 31: 235–241.CrossRefGoogle ScholarPubMed
22.Burri, R, Steffen, C, Herschkowitz, N. N-acetyl-L-aspartate is a major source of acetyl groups for lipid synthesis during rat brain development. Dev Neurosci 1992: 13: 403–411.CrossRefGoogle Scholar
23.d'Adamo, AF, Yatsu, FM. N-Acetyl-L-Aspartic acid and biosynthesis of brain lipids. J Neurochem 1966; 13: 961–965.CrossRefGoogle ScholarPubMed